RT Journal Article
SR Electronic
T1 Varicella Zoster Virus Vaccination in Patients With Immune-Mediated Inflammatory Diseases: Drivers and Barriers
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP jrheum.2025-0016
DO 10.3899/jrheum.2025-0016
A1 Goulenok, Tiphaine
A1 Carvalho, Maria
A1 Mageau, Arthur
A1 Terrier, Benjamin
A1 Hachulla, Eric
A1 Papo, Thomas
A1 Sacré, Karim
YR 2025
UL http://www.jrheum.org/content/early/2025/05/23/jrheum.2025-0016.abstract
AB Patients with immune-mediated inflammatory diseases (IMIDs) undergoing immunosuppressive therapy are at increased risk of herpes zoster (HZ).1 In line with international guidelines, the French national health authority updated the vaccination strategy against varicella zoster virus (VZV) in March 2024 and now recommends that immunocompromised persons aged ≥ 18 years be vaccinated with the recombinant VZV vaccine.2-4